News

PYC Therapeutics is set to begin Part B in its SAD study of the drug candidate, PYC-003, for polycystic kidney disease (PKD) patients.
Eleva has initiated dosing in its Phase I trial of its recombinant human complement Factor H (CPV-104) programme, for C3-glomerulopathy (C3G).
The FDA and the EMA have authorised AB Science’s confirmatory Phase III Study AB22007 trial of masitinib for mCRPC.
Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.
The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...
Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.
The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.
Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.
Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...
INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.
Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.
The nontuberculous mycobacteria (NTM) market across the seven major markets (7MM) and 5EU (US, France, Germany, Italy, Spain, ...